<?xml version='1.0' encoding='utf-8'?>
<document id="31090092"><sentence text="Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron."><entity charOffset="90-102" id="DDI-PubMed.31090092.s1.e0" text="Fesoterodine" /><entity charOffset="128-138" id="DDI-PubMed.31090092.s1.e1" text="Mirabegron" /><pair ddi="false" e1="DDI-PubMed.31090092.s1.e0" e2="DDI-PubMed.31090092.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31090092.s1.e0" e2="DDI-PubMed.31090092.s1.e1" /></sentence><sentence text="5-Hydroxymethyl tolterodine (5-HMT; the active fesoterodine metabolite) is metabolized via the cytochrome P450 (CYP) 2D6 and CYP3A pathways"><entity charOffset="0-27" id="DDI-PubMed.31090092.s2.e0" text="5-Hydroxymethyl tolterodine" /><entity charOffset="29-34" id="DDI-PubMed.31090092.s2.e1" text="5-HMT" /><entity charOffset="47-59" id="DDI-PubMed.31090092.s2.e2" text="fesoterodine" /><pair ddi="false" e1="DDI-PubMed.31090092.s2.e0" e2="DDI-PubMed.31090092.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31090092.s2.e0" e2="DDI-PubMed.31090092.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31090092.s2.e0" e2="DDI-PubMed.31090092.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31090092.s2.e1" e2="DDI-PubMed.31090092.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31090092.s2.e1" e2="DDI-PubMed.31090092.s2.e2" /></sentence><sentence text=" Mirabegron is a moderate CYP2D6 inhibitor and weak CYP3A inhibitor"><entity charOffset="1-11" id="DDI-PubMed.31090092.s3.e0" text="Mirabegron" /></sentence><sentence text=" Potential drug-drug interactions (DDIs) following coadministration of these 2 overactive bladder treatments were estimated using physiologically based pharmacokinetic models, developed and verified by comparing predicted and observed pharmacokinetic profiles from clinical studies" /><sentence text=" Models predicted and verified mirabegron and desipramine (CYP2D6 substrate) and 5-HMT and ketoconazole (strong CYP3A inhibitor) DDIs"><entity charOffset="31-41" id="DDI-PubMed.31090092.s5.e0" text="mirabegron" /><entity charOffset="46-57" id="DDI-PubMed.31090092.s5.e1" text="desipramine" /><entity charOffset="81-86" id="DDI-PubMed.31090092.s5.e2" text="5-HMT" /><entity charOffset="91-103" id="DDI-PubMed.31090092.s5.e3" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.31090092.s5.e0" e2="DDI-PubMed.31090092.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31090092.s5.e0" e2="DDI-PubMed.31090092.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31090092.s5.e0" e2="DDI-PubMed.31090092.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31090092.s5.e0" e2="DDI-PubMed.31090092.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31090092.s5.e1" e2="DDI-PubMed.31090092.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31090092.s5.e1" e2="DDI-PubMed.31090092.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31090092.s5.e1" e2="DDI-PubMed.31090092.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31090092.s5.e2" e2="DDI-PubMed.31090092.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31090092.s5.e2" e2="DDI-PubMed.31090092.s5.e3" /></sentence><sentence text=" Mirabegron model-predicted mean steady-state AUC and Cmax were within 11% of clinical observations"><entity charOffset="1-11" id="DDI-PubMed.31090092.s6.e0" text="Mirabegron" /></sentence><sentence text=" The predicted versus observed geometric mean ratio (GMR) of AUCinf for CYP2D6 substrates desipramine and metoprolol coadministered with mirabegron 100 or 160Â mg once daily were 3"><entity charOffset="90-101" id="DDI-PubMed.31090092.s7.e0" text="desipramine" /><entity charOffset="106-116" id="DDI-PubMed.31090092.s7.e1" text="metoprolol" /><entity charOffset="137-147" id="DDI-PubMed.31090092.s7.e2" text="mirabegron" /><pair ddi="false" e1="DDI-PubMed.31090092.s7.e0" e2="DDI-PubMed.31090092.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31090092.s7.e0" e2="DDI-PubMed.31090092.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31090092.s7.e0" e2="DDI-PubMed.31090092.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31090092.s7.e1" e2="DDI-PubMed.31090092.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31090092.s7.e1" e2="DDI-PubMed.31090092.s7.e2" /></sentence><sentence text="47 versus 3" /><sentence text="41 and 2" /><sentence text="97 versus 3" /><sentence text="29, respectively, indicating that the mirabegron model can be used to predict clinical CYP2D6 inhibition"><entity charOffset="38-48" id="DDI-PubMed.31090092.s11.e0" text="mirabegron" /></sentence><sentence text=" 5-HMT fractional clearance by CYP3A and CYP2D6 was verified from clinical DDI studies with a potent CYP3A4 inhibitor (ketoconazole) and inducer (rifampicin) in CYP2D6 extensive and poor metabolizers and with a moderate CYP3A inhibitor (fluconazole) in healthy volunteers"><entity charOffset="119-131" id="DDI-PubMed.31090092.s12.e0" text="ketoconazole" /><entity charOffset="146-156" id="DDI-PubMed.31090092.s12.e1" text="rifampicin" /><entity charOffset="237-248" id="DDI-PubMed.31090092.s12.e2" text="fluconazole" /><entity charOffset="1-11" id="DDI-PubMed.31090092.s12.e3" text="5-HMT" /><pair ddi="false" e1="DDI-PubMed.31090092.s12.e3" e2="DDI-PubMed.31090092.s12.e3" /><pair ddi="false" e1="DDI-PubMed.31090092.s12.e3" e2="DDI-PubMed.31090092.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31090092.s12.e3" e2="DDI-PubMed.31090092.s12.e1" /><pair ddi="false" e1="DDI-PubMed.31090092.s12.e3" e2="DDI-PubMed.31090092.s12.e2" /><pair ddi="false" e1="DDI-PubMed.31090092.s12.e0" e2="DDI-PubMed.31090092.s12.e0" /><pair ddi="false" e1="DDI-PubMed.31090092.s12.e0" e2="DDI-PubMed.31090092.s12.e1" /><pair ddi="false" e1="DDI-PubMed.31090092.s12.e0" e2="DDI-PubMed.31090092.s12.e2" /><pair ddi="false" e1="DDI-PubMed.31090092.s12.e1" e2="DDI-PubMed.31090092.s12.e1" /><pair ddi="false" e1="DDI-PubMed.31090092.s12.e1" e2="DDI-PubMed.31090092.s12.e2" /></sentence><sentence text=" 5-HMT AUCinf and Cmax GMRs for fesoterodine DDIs were all predicted within 1"><entity charOffset="1-5" id="DDI-PubMed.31090092.s13.e0" text="5-HMT" /></sentence><sentence text="26-fold of clinical observation, providing verification for the fesoterodine substrate model"><entity charOffset="64-76" id="DDI-PubMed.31090092.s14.e0" text="fesoterodine" /></sentence><sentence text=" The predicted changes in 5-HMT AUCinf and Cmax ratios for 8 mg fesoterodine when coadministered with 50 mg mirabegron were 1"><entity charOffset="64-76" id="DDI-PubMed.31090092.s15.e0" text="fesoterodine" /><entity charOffset="108-118" id="DDI-PubMed.31090092.s15.e1" text="mirabegron" /><entity charOffset="26-35" id="DDI-PubMed.31090092.s15.e2" text="5-HMT" /><pair ddi="false" e1="DDI-PubMed.31090092.s15.e2" e2="DDI-PubMed.31090092.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31090092.s15.e2" e2="DDI-PubMed.31090092.s15.e0" /><pair ddi="false" e1="DDI-PubMed.31090092.s15.e2" e2="DDI-PubMed.31090092.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31090092.s15.e0" e2="DDI-PubMed.31090092.s15.e0" /><pair ddi="false" e1="DDI-PubMed.31090092.s15.e0" e2="DDI-PubMed.31090092.s15.e1" /></sentence><sentence text="22-fold and 1" /><sentence text="17-fold, respectively, relative to 8 mg fesoterodine given alone"><entity charOffset="40-52" id="DDI-PubMed.31090092.s17.e0" text="fesoterodine" /></sentence><sentence text=" This modest increase in 5-HMT exposures by approximately 20% is considered clinically insignificant and would not require fesoterodine dose adjustment when coadministered with mirabegron within approved daily-dose ranges"><entity charOffset="123-135" id="DDI-PubMed.31090092.s18.e0" text="fesoterodine" /><entity charOffset="177-187" id="DDI-PubMed.31090092.s18.e1" text="mirabegron" /><entity charOffset="25-34" id="DDI-PubMed.31090092.s18.e2" text="5-HMT" /><pair ddi="false" e1="DDI-PubMed.31090092.s18.e2" e2="DDI-PubMed.31090092.s18.e2" /><pair ddi="false" e1="DDI-PubMed.31090092.s18.e2" e2="DDI-PubMed.31090092.s18.e0" /><pair ddi="false" e1="DDI-PubMed.31090092.s18.e2" e2="DDI-PubMed.31090092.s18.e1" /><pair ddi="false" e1="DDI-PubMed.31090092.s18.e0" e2="DDI-PubMed.31090092.s18.e0" /><pair ddi="false" e1="DDI-PubMed.31090092.s18.e0" e2="DDI-PubMed.31090092.s18.e1" /></sentence><sentence text="" /></document>